![Medivir, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ef445d97-1921-4188-965f-2a66631e32e9.png)
Medivir
2,98 SEK +6,43%1 investor følger denne virksomhed
Medivir is a pharmaceutical company. The company develops drugs and treatments with a focus on cancers and other serious diseases. The company invests in indication areas where available treatment methods are limited or completely lacking research. Collaborations with other partners are part of the business model, and drug development, as well as commercialization, are conducted either in-house or in partnership with other pharmaceutical companies. The head office is located in Huddinge.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
MVIR
Daglig lav / høj pris
2,8 / 2,99
SEK
Markedsværdi
341,56 mio. SEK
Aktieomsætning
656,19 t SEK
Volumen
226 t
Seneste videoer
Finanskalender
Delårsrapport
22.08.2024
Delårsrapport
06.11.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Linc AB | 11,3 % | 11,4 % |
HealthInvest Partners AB | 8,3 % | 8,3 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
![Medivir, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ef445d97-1921-4188-965f-2a66631e32e9.png)
Medivir to present updated clinical data for fostrox + Lenvima in HCC at ESMO Conference in September
Number of shares and votes in Medivir AB on 28 June 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
BioStock: Medivir presents promising results in difficult-to-treat patient population
Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI
Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility
Medivir: Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024
Medivir to present at Redeye Growth Day
Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
Resolutions at the Annual General Meeting in Medivir on 7 May 2024
BioStock: Double thumbs up for Medivir from the FDA
Redeye: Medivir Q1 2024 - Another TTP Improvement
![Medivir, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/db1e6f43-901e-4300-93a5-666393952317.png)